Insmed Provides Update on Supply of IPLEX(TM)
... RICHMOND, Va., July 27 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM ), a biopharmaceutical compan...g facility to Merck & Co., Inc. in March 2009, insmed no longer has the capability to manufacture IPLEX(...o consider its development options." About insmed ...Insmed to Present at Upcoming Healthcare Conferences
... RICHMOND, Va., Nov. 5 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM), a developer of follow-on biol... and CEO of Insmed, and Steve Glover, President of insmed Therapeutic Proteins, will be presenting at the 17...archived for a period of 90 days. About Insmed insmed Inc. is a biopharmaceutical company with unique pr...Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
... RICHMOND, Va., Dec. 6 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceutic...ce through access to these innovative follow-on biologics. About Insmed insmed Inc. is a biopharmaceutical company with unique protein process development...Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
... RICHMOND, Va., Oct. 14 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM), a developer of follow-on biol...t recorded 2007 sales of approximately $1 billion. insmed intends to seek approval of INS-19 and INS-20 in t... biologic version of Neulasta(R). About Insmed insmed Inc. is a biopharmaceutical company with unique pr...Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
... RICHMOND, Va., July 22 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq CM: INSM) a developer of follow-on bi...reased innovation in the field of biotechnology. insmed intends to request a meeting with the FDA to discu... combined 2007 worldwide sales of over $4 billion. insmed plans to launch its follow-on biologic versions of...Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
...MOND, Va., July 10, 2008 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM ), a developer of follow-on bi...s can be a scientific reality in the U.S. and that insmed is well positioned to be a leader in the field. De...of generic drugs today. Thus, based on these data, insmed intends to request a meeting with the FDA to discu...Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
...ALS Expanded Access Program Continues to Enroll - insmed Generates $2.3 million in Cost Recovery Revenue Th... RICHMOND, Va., April 29 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM), a developer of follow-on biol...velopment program. Follow-On Biologics Program insmed recently received regulatory approval from the Uni...Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
...es Regulatory Clearance RICHMOND, Va., April 16 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceutic...trates that the products have a high degree of similarity. About Insmed insmed Inc. is a biopharmaceutical company with unique protein process development...Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
... RICHMOND, Va., Feb. 5 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM), a developer of follow-on biol...ry pathway currently exists for FOBs in the U.S. insmed has launched a number of public initiatives to pro...educe costs for expensive biotech drugs. Following insmed CEO Geoffrey Allan's recent testimony before the U...Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study
... RICHMOND, Va.--(BUSINESS WIRE)--May 3, 2007 - insmed Inc. (Nasdaq:INSM) today announced positive result...ise known as ALS or Lou Gehrig's disease). About insmed insmed is a biopharmaceutical company focused on the deve...Insmed to Host Second Quarter 2009 Conference Call
... RICHMOND, Va., July 31 /PRNewswire/ -- insmed Inc. (Nasdaq: INSM ), a biopharmaceutical compan...ts financial results for the second quarter 2009. insmed intends to issue its quarterly financial results p...rnational), using passcode 53658791. About insmed ...Insmed Announces Addition to the Russell 3000(R) Index
... RICHMOND, Va., June 30 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM ), a biopharmaceutical compan... U.S. and global equity indexes on June 26, 2009. insmed was also added to the Russell Microcap(R) Index. ...stern Mutual Life Insurance Company. About insmed ...Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
... - insmed to Evaluate Potential Initiation of Phase II Trial...RICHMOND, Va. , June 25 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM ), a biopharmaceutical compan...itive function, gastrointestinal function or pain, insmed was unable to reach any conclusions regarding the ...Insmed CEO Resigns Due to Health Concerns
... RICHMOND, Va., June 15 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM ), a biopharmaceutical compan...lan has played a critical role in the evolution of insmed from its inception, navigating the Company through...encountered within the biotech sector, and putting insmed in an envied position of financial strength in the...Insmed Announces First Quarter 2009 Financial Results
... RICHMOND, Va., May 13 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM ), a biopharmaceutical compan...nd Net of finance and legal fees paid, insmed has received net proceeds to date of approximately... The FDA announced that it would allow insmed to provide access to IPLEX(TM) for investigational...Insmed Regains NASDAQ Compliance
... RICHMOND, Va., May 5 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM ), a biopharmaceutical compan...stock price had closed above $1.00 per share. insmed will continue to trade on The NASDAQ Capital Marke... bid price compliance is now closed. About insmed ...Insmed to Host First Quarter 2009 Conference Call
... RICHMOND, Va., April 23 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq CM: INSM ), a biopharmaceutical co...its financial results for the first quarter 2009. insmed intends to issue its quarterly financial results p...national), using passcode 62249241. About insmed ...Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
... insmed WILL CONTINUE TO MANAGE ALS EAP IN ITALY AND ALL I... RICHMOND, Va., March 30 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM ), a biopharmaceutical compan...oved in their country. Under the agreement, insmed will continue to be responsible for the IPLEX(TM) ...Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
... RICHMOND, Va., March 25 /PRNewswire-FirstCall/ -- insmed Inc. (Nasdaq: INSM ), a developer of follow-on b... reinstated on Monday, April 20, 2009. About insmed insmed Inc. is a biopharmaceutical company with unique pr...